Leap Therapeutics Inc (NASDAQ: LPTX) has seen a rise in its stock price by 22.86 in relation to its previous close of 0.29. However, the company has experienced a -21.08% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2025-03-31 that Leap Therapeutics (NASDAQ:LPTX ) Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET Company Participants Douglas Onsi – President and CEO Cyndi Sirard – Chief Medical Officer Jason Baum – Chief Scientific Officer Conference Call Participants Matthew Pipps – William Blair Swayampakula Ramakanth – H.C. Wainwright Operator Good morning.
Is It Worth Investing in Leap Therapeutics Inc (NASDAQ: LPTX) Right Now?
Company’s 36-month beta value is -0.11.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for LPTX is 30.76M, and currently, short sellers hold a 5.00% ratio of that floaft. The average trading volume of LPTX on April 02, 2025 was 2.58M shares.
LPTX’s Market Performance
LPTX’s stock has seen a -21.08% decrease for the week, with a -17.80% drop in the past month and a -87.74% fall in the past quarter. The volatility ratio for the week is 23.38%, and the volatility levels for the past 30 days are at 10.91% for Leap Therapeutics Inc The simple moving average for the past 20 days is -8.63% for LPTX’s stock, with a -83.47% simple moving average for the past 200 days.
Analysts’ Opinion of LPTX
Many brokerage firms have already submitted their reports for LPTX stocks, with Robert W. Baird repeating the rating for LPTX by listing it as a “Neutral.” The predicted price for LPTX in the upcoming period, according to Robert W. Baird is $1.25 based on the research report published on January 29, 2025 of the current year 2025.
Rodman & Renshaw gave a rating of “Buy” to LPTX, setting the target price at $8 in the report published on June 28th of the previous year.
LPTX Trading at -39.99% from the 50-Day Moving Average
After a stumble in the market that brought LPTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.53% of loss for the given period.
Volatility was left at 10.91%, however, over the last 30 days, the volatility rate increased by 23.38%, as shares sank -20.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -86.10% lower at present.
During the last 5 trading sessions, LPTX fell by -24.61%, which changed the moving average for the period of 200-days by -84.46% in comparison to the 20-day moving average, which settled at $0.3909. In addition, Leap Therapeutics Inc saw -87.55% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for LPTX
The total capital return value is set at -2.0. Equity return is now at value -141.94, with -110.79 for asset returns.
Based on Leap Therapeutics Inc (LPTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -226.69.
Currently, EBITDA for the company is -70.06 million with net debt to EBITDA at 0.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.41.
Conclusion
In a nutshell, Leap Therapeutics Inc (LPTX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
